SCHEMBL9966478

SCHEMBL9966478

N#CC1(c2ccc(OCc3ccccc3)cc2)CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.51
LMNA P02545 5/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALOX5 P09917 3/20 0.47
MMP1 P03956 1/20 0.45
MMP13 P45452 1/20 0.45
OPRM1 P35372 1/20 0.45
FFAR4 Q5NUL3 2/20 0.45
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.44
PTGS1 P23219 1/20 0.44
SLC6A2 P23975 1/20 0.44
CYP2C19 P33261 1/20 0.44
PTGS2 P35354 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6208176 0.90 MAOB (0.58) MAOBLMNASMN1; SMN2MMP13OPRM1
SCHEMBL6211633 0.87 MAOB (0.55) MAOBLMNASMN1; SMN2MMP13OPRM1
SCHEMBL2277113 0.87 MAOB (0.55) MAOBLMNASMN1; SMN2MMP13OPRM1
SCHEMBL6208936 0.86 MAOB (0.54) MAOBLMNASMN1; SMN2MMP13OPRM1
SCHEMBL11059742 0.86 MAOB (0.48) MAOBLMNASMN1; SMN2MMP13OPRM1
SCHEMBL21874085 0.84 MAOB (0.51) MAOBLMNASMN1; SMN2MMP13OPRM1
SCHEMBL11044387 0.83 MAOB (0.50) MAOBLMNASMN1; SMN2MMP13OPRM1
SCHEMBL9936964 0.82 ALDH1A1 (0.45) SMN1; SMN2ALOX5FFAR4KDM4EALDH1A1
SCHEMBL20028131 0.79 SMN1; SMN2 (0.48) LMNASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL9966397 0.79 MAOB (0.50) MAOBLMNASMN1; SMN2ALOX5MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2025-05-29 US disclosed
WO-2025104230-A1 BENZOXAZOLES AS MODULATORS OF IL-17A SANOFI (FR) 2025-05-22 WO disclosed
EP-2651930-B1 BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INT (DE) 2015-10-28 EP disclosed
US-9073895-B2 Biarylamide inhibitors of leukotriene production BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-07-07 US disclosed
US-9073895-B2 Biarylamide inhibitors of leukotriene production BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-07-07 US disclosed
US-20120322795-A1 BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-20 US disclosed
US-20120322795-A1 BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-20 US disclosed
WO-2012082817-A1 BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322795-A1 BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION LTB4R, LTB4R2, LTC4S MAOB 64/4885LMNA 351/4885SMN1; SMN2 4543/4885
US-20250171427-A1 THERAPEUTIC COMPOUNDS IL17A, IL2, IL36G MAOB 1748/4885LMNA 3412/4885SMN1; SMN2 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.